Evidence map›Paper›PMID 32780213›Full record

ArticleDer Pathologe2020

[Rare tumors as leading symptom of hereditary tumor syndromes].

Claudia Perne, Verena Steinke-Lange, Stefan Aretz, Isabel Spier

Abstract read
PubMed Publisher
In one paragraph

Article in Der Pathologe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Genetic diagnostics].Pathologie (Heidelberg, Germany) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Claudia PerneInstitut für Humangenetik, Universitätsklinikum Bonn, Bonn, Deutschland.
Verena Steinke-LangeMGZ - Medizinisch Genetisches Zentrum, München, Deutschland.
Stefan AretzInstitut für Humangenetik, Universitätsklinikum Bonn, Bonn, Deutschland.
Isabel SpierInstitut für Humangenetik, Universitätsklinikum Bonn, Bonn, Deutschland. isabel.spier@uni-bonn.de.
University Hospital Bonn · DEMedical Genetics Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonogenic hereditary tumor syndromes or tumor disposition syndromes (TDS) are based on germline/constitutional mutations in key genes of carcinogenesis. Early onset and a clustering of tumors belonging to a typical spectrum in the personal or family history are indicators for a hereditary form. In particular, rare specific tumors occur relatively frequently in the context of TDS.

methodsBased on a literature search the current article presents information on which TDS should be considered for differential diagnosis (DD) in the presence of a rare tumor.

resultsThe identification of a causal germline mutation in the index patient is important for the DD, the evaluation of recurrence risks, and predictive testing of asymptomatic at-risk family members. In TDS with autosomal dominant inheritance, it is often possible to identify several high-risk individuals in the affected families.

conclusionEarly detection and correct classification are of high clinical relevance as the patients and persons at risk can often be offered effective preventive procedures (surveillance, prophylactic operations), and in some cases, special therapeutic options exist. TDS are paradigmatic for an extremely successful concept of preventive oncology and personalized medicine. The introduction of new methods of high-throughput sequencing (next generation sequencing) enables a more effective genetic diagnosis, but also poses a challenge for the interpretation of findings and counseling. Referral to multidisciplinary expert centers is useful for care of the families.

Indexed as

Genetic Predisposition to DiseaseNeoplastic Syndromes, HereditaryGenetic TestingGerm-Line MutationHigh-Throughput Nucleotide SequencingHumansGene panelGermline mutationMonogenic hereditary tumor syndromesSurveillanceTumor disposition syndromes

Identifiers

PMID32780213
OpenAlexW3048717454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.